Premium
Efficacy of rituximab in refractory antisynthetase syndrome
Author(s) -
Limaye V.,
Hissaria P.,
Liew C.L.,
Koszyka B.
Publication year - 2012
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/j.1445-5994.2011.02702.x
Subject(s) - antisynthetase syndrome , rituximab , medicine , refractory (planetary science) , dermatology , intensive care medicine , immunology , antibody , autoantibody , physics , astrobiology
We report the successful use of repeated administration of rituximab in a patient with antisynthetase syndrome refractory to conventional immunosuppressive medications. A literature review revealed that previous experience with rituximab in this condition has been sparse. The rationale for the use of B‐cell depleting therapies in antisynthetase syndrome has been explored in light of the current understanding of the pathogenesis of this condition.